About AZN
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,
Three plain-English paragraphs — current state, historical base rate, and interpretation — so you walk away with context, not a dashboard.
Snapshot
How is AZN doing right now?
In plain terms: AZN is 7% below its highest-ever price. Dipsern checks every past time it was this far down and grades how the next 90 days usually went.
AstraZeneca plc (AZN) sits 7.0% off its peak and is currently in a shallow pullback, last printing at $14,456. Shallow pullbacks like this are routine — historically UK Stocks assets revisit a 5-10% dip several times a year, and most resolve back to highs within weeks.
Historical base rate
What history says at this drawdown
AZN reaches this drawdown band repeatedly in its history (1643 observations), which is a large sample for the segmentation engine to compute a stable median forward return. The engine uses a rolling 90-day window and gives more weight to recent years — this lets the signal adapt to regime changes (e.g., post-COVID volatility) without losing the long-run base rate.
Interpretation
What this means for AZN
Drawdown-based signals work across asset classes but the magnitude of meaningful moves varies. Dipsern computes the segmentation per-asset so the bands are calibrated to AZN's own volatility history. Shallow pullbacks are where dip-buying frameworks start to pay off, but only marginally. The median forward return in shallow bands is usually positive but not dramatic.